Alluvi, initially dubbed LY3414901, represents a significant advancement in obesity management. This dual -action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor https://alluvi-healthcare643274.tinyblogging.com/alluvi-a-detailed-dive-into-retatrutide-s-potential-87642378